Product Images Aripiprazole

Aripiprazole is a medication that comes in 5mg tablets. The National Drug Code for this medication is 70518-2536-00 and it expires on an unknown date. The manufacturer of the medication is Torrent Pharma Inc, NJ, and the medication is packaged with a quantity of 30 tablets per package. It is important to keep this and all other medication out of reach of children. The recommended storage temperature is between 15-30°C (59-86°F). The use of this medication should be done in accordance with the instructions found in the package insert. This medication is available by prescription only and it was repackaged by RemedyRepack Inc, PA.*

This is a chart showing the effects of different drugs on the pharmacokinetics of Aripiprazole, a medication often used to treat schizophrenia and bipolar disorder. The chart displays Aripiprazole's fold change and 90% confidence interval when interacting with specific drugs like ketoconazole, quinidine, carbamazepine, famidine, valproate, lithium, and lorazepam. The fold change is relative to the reference without the interacting drug.*

This is a figure displaying the effects of aripiprazole on the pharmacokinetics of several other drugs, including lamotrigine, lithium, omeprazole, lorazepam, and escitalopram. The fold changes and 50% confidence intervals are shown on the y-axis, and the drugs are listed on the x-axis. The graph shows the relative change to the reference (without the interacting drug) from 0 to 30 on the x-axis.*

The image is a figure that shows the effects of intrinsic factors on the pharmacokinetics of aripiprazole, an antipsychotic medication. The figure includes comparisons of different special populations, such as poor versus extensive metabolizers, males versus females, and individuals of different ages. Additionally, the figure compares the pharmacokinetics of aripiprazole in individuals with varying degrees of hepatic and renal impairment. The information is summarized in fold changes and 90% confidence intervals for AUC and Cmax values.*

The image shows the effects of different intrinsic factors on the pharmacokinetics of dehydro-aripiprazole, presented in fold change and S0% CI. These factors include CYP2D6 metabolizer status, gender, age, hepatic impairment, and renal impairment. The graph displays the changes relative to the reference values for each factor.*

This is a graph representing the cumulative proportion of relapse in patients with schizophrenia study. The graph shows the comparison between aripiprazole and placebo. The number of subjects at risk is also shown. The x-axis shows the total number of days from randomization.*

The figure shows the Kaplan-Meier estimation of the cumulative proportion of patients with relapse in Bipolar Study 7. The graph displays two groups, Aripiprazole, and Placebo. The number of subjects at risk is displayed below the graph. The X-axis displays the number of days from randomization, starting with 0 days and ending with 182 days.*

This is a graph showing the least square means of change from baseline in YGTSS TTS by week in a Tourette's Disorder Study. The text also includes the change in YGTSS total tic score from baseline and a table with the weeks of treatment and least square means change in YGTS.*